Error loading player: No playable sources found

AM23-SN-02-O

AM23-SN-02-O: Navigating the FDA Licensure Pathway (Enduring)

Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$30
Standard Price
Members save $5

This session will review the steps required when applying to the Food and Drug Administration (FDA) for an original Biologics License Application (BLA) to manufacture, modify, market and distribute blood components and biologics in interstate commerce. An overview of the initial submission requirements will be provided. Changes to an approved application which require supplemental reporting including labeling, production processes, quality control, equipment and facilities will be outlined. The change reporting parameters, requisite materials and implementation time frames for Changes being Effected (CBE and CBE30) or Prior Approval Supplement (PAS) will be discussed. The applicability and content of a comparability protocol for submitting an alternate procedure will be described along with the implementation timeframes. The Annual Reporting (AR) obligations to FDA for licensed facilities will be defined. The pathways available to submit these various applications and supplements will be examined along with a demonstration of the sign-on and navigation of the FDA electronic submission process. Lessons learned through these various application processes will be shared to help streamline the learning curve for new submitters. If you’re just starting down the FDA registration and licensing pathway or a seasoned navigator hoping to avoid inadvertently taking the wrong fork in the road, this session is for you!

Learning Objectives

  • Understand Biological License Application (BLA) contents and the BLA review process.
  • Discuss labeling, production process, quality control, equipment and facility changes that must be reported to FDA.
  • Categorize the three reporting categories for changes to an approved application.
  • Identify the time frames for the different reporting categories.
  • Summarize the methods to be used to submit and amend a Biologics license.

Speakers

Speaker Image for Susan Wilson
Susan M. Wilson, BS, MLS(ASCP)SBB
Speaker Image for Kathleen Hopping
Kathleen Hopping, MS, BS, RAC
Senior Director, Regulatory Affairs - Licensing, Vitalant
Speaker Image for Wendell Jones
Wendell Jones, MS, MLS(ASCP)SBB, CQA(ASQ)
Executive Director, Quality and Regulatory Services, LifeShare Blood Center

Tracks

Related Products

Thumbnail for AM24-MN-17-O: Making Learning Stick – Effective Training for Blood and Biotherapies Professionals (Enduring)
AM24-MN-17-O: Making Learning Stick – Effective Training for Blood and Biotherapies Professionals (Enduring)
The future of the blood and biotherapies fields depends on our ability to prepare a new generation of leaders and skilled professionals to continue advancing the field…
Thumbnail for AM24-MN-04-O: There’s a Blood Donation Bill Proposed to Require WHAT!?—Navigating the Legislative Proposal and Change Process (Enduring)
AM24-MN-04-O: There’s a Blood Donation Bill Proposed to Require WHAT!?—Navigating the Legislative Proposal and Change Process (Enduring)
Today’s leaders increasingly find themselves immersed in the world of legislation and advocacy, which is an unfamiliar space for many…
Thumbnail for AM24-SN-14-O: Blood Donation, Race and Transfusion Medicine: Looking Back to Move Forward (Enduring)
AM24-SN-14-O: Blood Donation, Race and Transfusion Medicine: Looking Back to Move Forward (Enduring)
Race is a sociopolitical and not biological construct. As such, the use of race-based algorithms and disease associations has caused demonstrable harm such as delayed kidney transplant referral and missed diagnoses. The field of transfusion medicine is not immune…